To evaluate the effectiveness of a culturally appropriate lifestyle intervention combined with orlistat in producing weight loss with obese Mexican-American women. SUBJECTS: Mexican-American women (N ¼ 108), aged 21-65 y, with a body mass index (BMI) Z27 kg/m 2 were randomized to 1 y of treatment with orlistat and a culturally tailored lifestyle modification intervention (OLM; n ¼ 56) or a wait-list control group (WLC; n ¼ 52). DESIGN: A randomized, controlled, open-label 12-month study. Orlistat was dosed at 120 mg, three times per day. The OLM intervention included behavior modification, a low-fat (r30% of total daily calories) diet, and moderate physical activity (Z150 min/week). MEASUREMENT: Primary outcomes included changes in body weight (kg), BMI, waist circumference, blood pressure, glucose, and lipids. RESULTS: A total of 72 (37 OLM, 35 WLC) and 66 participants (32 OLM, 34 WLC) completed the 6-and 12-month follow-ups, respectively. Repeated-measures ANOVA demonstrated a significant time Â treatment interaction (Wilks' l ¼ 12.61; Po0.001), indicating that OLM-treated patients achieved significant weight loss relative to the WLC group during the study (mean percentage weight loss7s.e.m.; À8.1%71.2 vs À1.6%70.7 at 6 months and À8.8%71.5 vs À0.2%71.0 at 12 months, respectively). OLM-treated patients also experienced significant reductions in waist circumference, low-density-lipoprotein, and total cholesterol. CONCLUSIONS: This study demonstrates the effectiveness of an intervention combining orlistat and lifestyle modification with Mexican-American women, a population with substantial risk for obesity. 
Mexican Americans are also predisposed to develop more atherogenic patterns of body fat distribution. 7, 8 Early weight gain and centralized and upper body fat have been associated with the onset of diabetes in Mexican Americans. 9 For example, Mexican Americans with centralized obesity are at significantly greater risk for low HDL-C, high total cholesterol, and high blood glucose than nonobese individuals or those with nonabdominal obesity. 8 In addition, 50% of Mexican-American adults 35 y or older either have diabetes themselves or have a first-degree relative with diabetes. 10 Modest weight loss can have a beneficial effect on cardiovascular disease and diabetes risk factors. 1, [11] [12] [13] [14] It is likely that Mexican Americans, and other minority groups, would also experience these same benefits with modest weight loss. However, ethnic minorities tend to have higher attrition and lose less weight than nonminorities in behavioral weight loss trials. 15 For example, Kumanyika et al 16 reported that African-American women lost 42 kg less than Caucasian women in two different hypertension clinical trials with behavioral weight loss programs. In a more recent study, this finding was replicated with older African Americans. 17 The results of trials provide a somewhat mixed picture of the success of behavioral weight loss programs for ethnic minorities, with shorter trials tending to demonstrate significant weight losses, but longer studies (ie, 1 y or more) demonstrating nonsignificant weight losses and moderate to high attrition. 15, [18] [19] [20] [21] Because of these uncertain outcomes and the significant problem of obesity among minority populations, some investigators have included pharmacotherapy in their interventions. For example, McMahon et al 22 evaluated the efficacy of sibutramine, a serotonin and norepinephrine reuptake inhibitor, in a 1-y randomized, placebo-controlled, multicenter trial with African Americans and Caucasians. They found that African-American patients (39% of treated patients) lost an average 4.0% of their initial body weight, which was similar to the 4.9% change found in treated Caucasian patients (African-American and Caucasian placebo patients lost 0.0 and 0.6%, respectively). MartinezCuellar et al 23 examined weight loss with sibutramine among 69 Mexican patients (n ¼ 35 in the sibutramine group, n ¼ 34 in the placebo condition) in a 6-month randomized, doubleblind, placebo-controlled trial. At the end of 6 months, sibutramine-treated patients lost 14.2 kg compared to 0.9 kg for placebo patients. However, these large weight loss differences must be interpreted with caution because of differential drop-out in this study, that is, 37% of those receiving sibutramine vs 74% of the placebo patients were lost to follow-up. 23 Unfortunately, the above studies were limited because they did not optimally combine pharmacotherapy with an intensive or culturally appropriate lifestyle-modification program, a common problem in obesity drug studies. 24 In addition, no long-term randomized studies have examined the effectiveness of noncentrally acting antiobesity agents among ethnic minorities. The purpose of this study was to test the effectiveness of a culturally appropriate lifestyle intervention combined with orlistat, a lipase inhibitor, with obese Mexican-American women in producing weight loss and improving cardiovascular risk factors.
Methods

Participants
Our inclusion criteria required that participants be female, of Mexican origin, aged 21-65 y, and have a BMI equal to or greater than 27 kg/m 2 . Subjects were limited to women, as our previous experience suggests that even when recruited, Mexican-American men are unlikely to enroll in a weightloss study in large enough numbers to allow for statistical comparisons between male and female subjects. 18, 19, 25 This may be due in part to the emphasis in lifestyle classes on learning to prepare foods differently, which is largely the responsibility of women. Subjects with borderline or definite hypertension or with diabetes treated with oral hypoglycemic agents were also allowed to participate with their physician's consent. Potential participants were excluded if they had serious medical conditions that precluded participation, if their physician was unwilling to consent to their participation, or if they were not going to stay in the Houston area during the full 12 months of the study. The Institutional Review Board of Baylor College of Medicine approved the study. A total of 135 patients were initially screened, of which 108 were eligible and willing to participate in the 1-y trial, which was conducted from March 2000 to March 2002. Figure 1 provides a detailed schematic of the study design and patient flow.
Patients were randomly assigned to orlistat and lifestyle modification (OLM) or to a wait-list control (WLC) group. Characteristics of participants in both groups are presented in Table 1 .
There were no significant differences between patients randomized to OLM or WLC with regard to demographic or baseline health status factors.
Procedures
Participants randomized to OLM condition attended 24 weekly intervention classes, six bimonthly, and three monthly maintenance classes led by a bilingual Mexican American registered dietitian with training in cognitivebehavioral modification. Each class lasted 60 min and included (1) a nutrition component including food demonstrations of modified traditional dishes; (2) problem solving and role-playing of behavioral change skills, such as identifying problem eating situations, or setting an exercise objective; (3) discussion and rehearsal of social support strategies; and (4) discussions on physical activity. The OLM intervention was designed to be culturally appropriate for the target population by including the use of bilingual materials, having intervention and maintenance classes taught by a bilingual Mexican-American instructor, modification of native diets, and the use of culturally tailored rationales for diet and exercise modification (eg, emphasizing the importance of family involvement and improving health rather than just appearance). 24, 25 Orlistat. Participants randomized to treatment received instructions to take 120 mg of orlistat three times a day at meals for the 12 months of the study. Participants were also instructed to take one vitamin and mineral capsule daily to replace fat-soluble vitamins. Medication was dispensed by a registered nurse at appropriate class sessions.
Behavior modification. Strategies included self-monitoring, stimulus control, contingency management, cognitive restructuring, stress management, and social support. 26 Nutrition. Participants were instructed to lower their caloric intake by at least 500 calories per day in order to achieve a slow gradual weight loss of approximately 1 pound/week. Fat intake was limited to approximately 30% of total daily calories. Participants recorded their food intake in food diaries on a weekly basis and were also taught to calculate their total daily calories and fat grams. A nutrition manual (ie, LIFESTEPS r : your personal plan for weight management, 3rd edn, 1998, Dairy Council of Utah/Nevada), which contains 16 weight loss lessons and 11 maintenance activities, was used for the nutrition intervention.
Physical activity. The primary physical activity objective was to increase activity to a minimum of five times per week for 30 min per session for a total of 150 min or more per week. 27 The instructor encouraged participants to use walking as the primary form of physical activity. Incorporating increased physical activity into daily routines was discussed at each class and suggestions provided (eg, using stairs, taking short walks during breaks). 28 Exercise contracts were also used to promote physical activity and incentives provided to motivate participants to become more physically active. Blood pressure. Blood pressure was measured in the seated position according to the guidelines from Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). 29 Systolic and diastolic blood pressures were determined manually using a mercury sphygmomanometer by the first and fifth Korotkoff's sounds, respectively. For each subject, the same arm and the same appropriately sized cuff were used throughout the study. In addition, all readings were taken at approximately the same time of day (72 h). For each indicated measurement of blood pressure, three separate readings at approximately 2 min intervals were recorded and averaged.
Side effects/adverse events. Adverse events were defined as any change in structure (signs) or function (symptoms) of the body, or laboratory value that occurred while the subject participated in the study. All adverse events were assessed by the study nurse at classes and assessment visits.
Medication use and adherence. Medication adherence was monitored by requiring subjects to return all medication containers, whether used or not. The containers were inventoried and the number of capsules remaining in each bottle from the preceding visit was entered on the Study Medication Accountability Log/Dispensing Record. Research has demonstrated consistently that pill counting and monitoring of health outcomes are associated with improved treatment outcomes.
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Statistical analysis Means7s.d. (or s.e. when indicated) or percentages were calculated for all baseline demographic and clinical variables. t-Tests and w 2 analyses were used to evaluate group differences on baseline characteristics and differences between participants who remained in the study and those who dropped out at 6 and 12 months. A two-group (OLM vs WLC) repeated measures analysis of variance (RANOVA) over three time periods (baseline, 6-and 12-month time points) was carried out using body weight (kg) and BMI as the primary end points. As recommended by the CONSORT guidelines, 33 we developed models for both completers (N ¼ 66) and intention-to-treat (ITT) models using the last observation carried forward (LOCF) method (N ¼ 108). In addition, all reported data are the actual observed values rather than those derived using the LOCF values, unless specifically noted.
Results
Preliminary analysesFattrition and medication use At the 6-month follow-up, 33.9% of OLM-treated and 32.7% of WLC participants had been dropped from the study (P ¼ 0.892). At the end of the study (12 months), 42.9% of OLM-treated and 34.6% of WLC participants had been dropped from the study (P ¼ 0.380). There were no significant differences between those who remained in the study and those who dropped other than drop-outs at both 6 and 12 months were younger than those who continued in the study (44.878.6 vs 39.679.3, P ¼ 0.005 at 6 months; 45.178.5 vs 39.879.3, P ¼ 0.003 at 12 months). In addition, no patients who withdrew from the study reported drug side effects as a reason for withdrawal. We also examined pill use as a measure of treatment adherence among the OLM-treated patients. We estimated adherence by examining medication use as a function of number of pills providedFnumber of pills returned/pills provided. OLM-treated patients used 88.2% of their pills provided. Not surprisingly, OLM-treated patients were also more likely to achieve the NIH/NHLBI 1 guideline-based goals for weight loss. Figure 3 presents the proportion of OLM-treated and WLC participants achieving 5 and 10% weight losses at 6 and 12 months. Substantially larger numbers of OLM-treated patients met the 5% (Po0.000 for both 6 and 12 months) and 10% (P ¼ 0.008 for both 6 and 12 months) goal weight losses than WLC patients.
*Wilks' Lambda = 12.61; p < 0.001 for the treatment by time interaction, demonstrating that the OLM-treated group achieved significant weight loss relative to the WLC group at the 6-and 12-month measurements. Tables 1 and 2 provide the values for all cardiovascular outcomes at baseline, 6 and 12 months. OLM-treated patients also experienced significant improvements in some cardiovascular risk factors. There were significant treatment effects on reduction in waist circumference (Wilks' l ¼ 4.01, P ¼ 0.030), LDL cholesterol (Wilks' l ¼ 5.60, P ¼ 0.006), and total cholesterol (Wilks' l ¼ 3.80, P ¼ 0.029). Figure 4 illustrates changes in LDL cholesterol over the course of the trial. None of the changes in other risk factors was statistically significant.
Adverse events
Adverse events data were collected on OLM-treated patients monthly, but are reported for the 6-and 12-month visits. No adverse events were reported that required trial termination. Table 3 summarizes the frequency of expected gastrointestinal side effects for OLM-treated patients. At 12 months, the most frequently occurring events were oily spotting, fecal urgency, fatty/oily stool, and increased number of bowel movements.
Discussion
Patients treated with OLM lost significantly more weight than those in the WLC group. Treated patients who completed the study lost an average of 7.9 kg at 6 months and 8.6 kg at 12 months, or 48% for completers. These weight losses are similar to those reported for orlistat in a recent pharmacotherapy meta-analysis, where orlistat yielded an average weight loss of 7.1 kg in six randomized, placebo-controlled trials. 34 In addition, substantial proportions of OLM-treated patients achieved the thresholds regarded by the US Food and Drug Administration as desirable. 35 Nearly 60% of completers (41% ITT) lost 5% of initial body weight at 12 months and 31% of completers (21.4% ITT) lost 10% of initial body weight (see Figure 3) . and 53% of their participants who received orlistat or placebo for 1 y. Orlistat was well tolerated in this study and no patients were discontinued due to significant adverse events. As would be expected given the pharmacology of orlistat, treated patients reported side effects such as oily spotting, oily stool, fecal urgency, and increased number of bowel movements. Similar side effects have been reported for orlistat by other investigators. 35, 36, 38 This study was limited because the independent effect of orlistat could not be ascertained due to the design of our study, that is, we used a WLC group instead of a doubleblind, placebo-controlled design. In addition, we could not examine ethnic differences in weight loss because we enrolled only Mexican-American women. However, we were interested in the effectiveness of a comprehensive obesity management program that combined pharmacotherapy and lifestyle modification in a Mexican-American population when compared to no treatment. In addition, the long-term efficacy of orlistat has been established previously in doubleblind, placebo-controlled trials.
36,38 While we could not examine ethnic differences in weight loss, treated Mexican- American participants achieved weight losses similar to those reported in previous orlistat trials. 34 This study focused on demonstrating weight loss in an underserved population; thus we limited our enrollment to overweight and obese Mexican-American women primarily with class I and II obesity 1 without substantial medical comorbidities, similar to most obesity drug studies. 24 It was not surprising that we did not significantly impact some of the secondary outcomes such as blood pressure. However, OLM-treated patients did experience significant reductions from baseline in LDL and total cholesterol. In addition, nearly 26% of our sample (28.6% in the OLM group, 23.1% in the WLC group) had BMIs that categorized them as class III obesity (BMI Z40kg/m 2 ). 1 Therefore, while our sample may not have been as representative of obese patients with significant medical comorbidities, it over-represented patients with extreme obesity (ie, class III). 39 In conclusion, this study documents the effectiveness of a comprehensive obesity management intervention that combined pharmacotherapy (orlistat) and lifestyle modification with Mexican-American women, a population with substantial risk for overweight and obesity. 1, 5 However, Sjöström et al 40 recently presented results of a large, multicenter randomized trial of orlistat and lifestyle modification in a Swedish sample with similar results. Patients received either lifestyle modification and orlistat or lifestyle modification and placebo, and the primary end points were the development of type II diabetes and weight change. After 4 y of treatment, patients assigned to orlistat and lifestyle modification lost an average of 6.9 kg, while patients with lifestyle modification and placebo lost significantly less weight (4.1 kg; Po0.001). In addition, orlistat-treated patients also experienced a significant 37% reduction in risk (P ¼ 0.0032) for developing type II diabetes when compared to those receiving lifestyle modification and placebo. OLM-treated patients experienced statistically significant and clinically important weight losses when compared to patients randomized to the WLC. In addition, treated patients also experienced reductions in LDL and total cholesterol, potentially lowering their risk for cardiovascular disease, results also documented by Sjöström et al. 40 The drug was well tolerated and participant attrition was similar to that reported in other pharmacotherapy studies. While some previous studies have reported that ethnic minorities are less likely to achieve benefits from participating in obesity management trials, 16, 17 the results of this study with
Mexican-American women suggest that the combination of orlistat with a culturally appropriate lifestyle intervention can produce weight losses similar to those reported in other orlistat trials. 34 
